Astellas Doses First Patient in Phase 3 Study of setidegrasib in Previously Treated KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer

Why it matters

An early Phase 3 start for a KRAS G12D degrader signals pipeline progress but no efficacy or revenue data yet.

Details

- Study evaluates novel, investigational KRAS G12D-targeted protein degrader setidegrasib versus docetaxel in previously treated patients with advanced NSCLC - - Milestone marks second Phase 3 study of setidegrasib initiated within six months - TOKYO, Sept. 23, 2026 /PRNewswire/ --...

Related assets & topics

Sources

• prnewswire · 2026-09-23 23:30 UTC

Related stories

• Aurora Cannabis Files Application with Alberta Securities Commission to Protect Company Shareholders Having Identified Several Deficiencies in Curaleaf's Hostile Bid Disclosure
  News · 2026-09-23 22:28 UTC
• FDA Advisory Committee Votes In Favor of Approval of GRAIL's Galleri® Multi-Cancer Early Detection Test
  News · 2026-09-23 22:17 UTC
• Doseology Announces Proposed Shares-for-Debt Settlement and Resignation of Director
  News · 2026-09-23 22:16 UTC
• Global Flow Cytometry Market to Reach USD 11.14 Billion by 2034 at 9% CAGR as Rising Adoption in Clinical Diagnostics, Growing Multiparameter Cell Analysis, and Advances in High-Parameter Flow Cytometry Accelerate Market Growth, Reports Maximize Market Research
  News · 2026-09-23 22:00 UTC
• Global Vitiligo Treatment Market to Reach USD 2.97 Billion by 2034 at 5.8% CAGR as Rising Disease Prevalence, Growing Aesthetic Awareness, and Advances in Targeted Therapies Accelerate Market Growth, Reports Maximize Market Research
  News · 2026-09-23 21:45 UTC

More on the feed →